General Atlantic picks JPMorgan to lead revived IPO effort, source says. By Thomson Reuters Aug 17, 2026 | 12:56 PM By Echo Wang Aug 17 (Reuters) - Investment firm General Atlantic has tapped JPMorgan Chase to lead its initial public offering, according to a source familiar with the matter, reviving listing plans that had been stalled for nearly three years. The New York-based company has also hired Morgan Stanley and Goldman Sachs for the IPO, which could take place as soon as this year, the source said. The source, who requested anonymity because the discussions were private, said talks are ongoing and offering details, including the number of banks involved, could change. General Atlantic, Morgan Stanley and Goldman Sachs declined comment. JPMorgan did not immediately respond to a Reuters request for comment. The firm confidentially filed for a listing in December 2023, but delayed the offering due to market volatility. The U.S. IPO market has rebounded in recent months, with the listing of Elon Musk's SpaceX earlier this year among the most prominent offerings, as strong investor sentiment has encouraged more companies across sectors to go public. General Atlantic manages about $130 billion in assets and has invested a total of $121 billion since its inception, according to its website. Its global investment portfolio includes artificial intelligence company Anthropic, India's digital payments firm PhonePe and Mexican bank Banamex. Bloomberg News was first to report the hiring of JPMorgan as lead underwriter, while The Wall Street Journal was first to report the revival of the listing plans. (Reporting by Pritam Biswas in Bengaluru; Editing by Tasim Zahid)

The FinTech sector recorded $2.039 billion in funding across 27 deals this week, with significant investments directed towards a health benefits business and

Avere Therapeutics announced a $500 million private placement to advance AVR-001, its once-weekly oral IL-23 receptor antagonist for inflammatory diseases. Leading healthcare investors including Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, and Wellington Management participated in the funding round. Combined with a previously announced $320 million concurrent private investment, the proceeds will fully fund Avere's operations through 2029. The financing will close alongside Avere's merger with NextCure, expected in the second half of 2026. Upon completion, the combined company will operate as Avere Therapeutics and trade on Nasdaq under ticker symbol "AVRX." Avere is initially developing AVR-001 for psoriasis, with potential expansion into ulcerative colitis, Crohn's disease, and psoriatic arthritis.